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MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. It has been found that numerous miRNAs exhibit misregulated expression in multiple types of cancers and are often associated with diagnosis, staging, progression, prognosis and response to clinical therapies (reviewed in [1] ). The miR-200 family includes five members: miR-200a, miR-200b, miR-200c, miR-429 and miR-141. It plays a critical regulatory role in two processes which are associated with metastasis and prognosis of malignant tumors: epithelial-to-mesenchymal transition (EMT) and mesenchymal-toepithelial transition (MET) [2] [3] [4] [5] . EMT is a reversible series of events in which an epithelial cell loses cell-cell contact and acquires mesenchymal properties [6] . The miR-200 family is a key regulator of the epithelial phenotype by directly targeting two transcriptional repressors of E-cadherin (encoded by CDH1): ZEB1 and ZEB2 (also named TCF8 and SIP-1). Deficiencies in miR-200 expression will lead to the accumulation of ZEB1 and ZEB2, and subsequently silence the CDH1 and promote EMT [2, 3] . MET is the reverse process of EMT. The miR-200 family is overexpressed during MET, then inhibits ZEB1 and ZEB2 expression and promotes the synthesis of E-cadherin [4, 5] .
MiR-200c is the most representative miRNA among the miR-200 family. It plays a critical role in the regulation of both the EMT and MET processes [4, 7] . Since 2006 [8] , multiple studies have demonstrated the prognostic value of miR-200c in different cancers, including serous ovarian cancer [9] , bladder cancer [10] , pancreatic cancer [11] , esophageal cancers [12] , lung cancer [13] and endometrial cancer [14] . Nearly half of these studies revealed a significant association between miR-200c overexpression and poor prognosis [8, 9, 13, [15] [16] [17] [18] [19] [20] [21] [22] . However, other studies reported an insignificant association or opposite conclusions [10-12, 14, 23-30] . The evidence from individual study is insufficient to conclude whether miR-200c can be used as a potent biomarker for prognosis. Consequently, a systematic and comprehensive meta-analysis is urgently required to explore the relationship between miR200c expression and prognosis of cancer patients.
Through a systematic review and meta-analysis of global literatures, this study performed a comprehensive and objective evaluation of the prognostic significance of elevated tissue-and blood-based miR-200c levels in cancer patients. Moreover, we analyzed the underlying mechanism for the regulatory roles of miR-200c in EMT and MET that are associated with tumor metastasis and patient prognosis.
Materials and Methods
This meta-analysis was carried out in accordance with the Systematic Reviews and Meta-Analyses (PRISMA) and the Observational Studies in Epidemiology (MOOSE) guidelines [31] .
Search strategy
Literatures were searched through PubMed, Embase and the Cochrane Library (last update by May 20, 2014) . Keywords used in the search strategy were "microRNA-200c OR miR-200c" (all fields) AND "tumor OR tumour OR neoplasm OR cancer OR carcinoma" (all fields). We did not impose any advanced limitations when searching the database. The reference lists of identified articles were also screened to further identify potential studies. The comprehensive database search was carried out independently by two authors (Y. Shao and Y. Geng).
Inclusion and exclusion criteria
Literatures that were eligible for inclusion in this systematic review met the following criteria: (1) the expression of miR-200c in cancer tissue or blood, (2) investigation of the relationship between miR200c expression level and survival outcome. Studies with sample size ≥30 and provided sufficient data to estimate the hazard ratio (HR) and 95% confidence intervals (CI) were advanced to inclusion in the meta-analysis. Considering the tumorigenesis and metastasis mechanism of hematological malignancy is different from other tumors of epithelial origin, studies of hematological malignancy were excluded. When multiple studies reported on the same patient cohort, only the most recent or complete study was selected. Case reports, letters, reviews, conference abstracts and animal trials were excluded. Two reviewers independently evaluated titles and abstracts of the identified articles and subsequently excluded those that were considered irrelevant. The full text of enrolled articles was carefully examined for comprehensive evaluation. Disagreement from two reviews was resolved by consensus.
Data extraction and quality assessment
The required information from all eligible studies was collected by two researchers independently, which included first author's surname, publication year, origin of population, tumor type, sample number, tumor stage, lymph node metastasis, follow-up period, source of miRNA, miR-200c assessment methods and the cut-off definition, and HR of miR-200c expression for overall survival (OS), disease-free survival (DFS) and relapse-free survival (PFS) as well as corresponding 95% CIs. If a study reported both the results of univariate and multivariate analysis, only the latter was selected because it has increased precision due to accounting for confounding factors.
The quality of each study was assessed independently by two researchers according to the NewcastleOttawa Quality Assessment Scale (NOS) [32] . For quality assessment, scores ranged from 0 (lowest) to 9 (highest), and studies with scores of 6 or more were rated as high quality.
Statistical analysis
High and low expression of miR-200c was defined according to the cut-off values provided in the articles. HRs and their 95% CIs were combined to measure the effective value of miR-200c expression on prognosis. If the statistical variables were described in the study, we extracted them directly. Otherwise, they were calculated from available numerical data in the articles according to the methods described by Tierney [33] . The data from Kaplan-Meier survival curves were read by Engauge Digitizer version 4.1, and three independent researchers read the curves to reduce reading variability. We also sent e-mail to the corresponding authors of eligible articles requesting additional information and original data needed for the meta-analysis. An observed HR greater than 1 indicated a worse prognosis in patients with miR-200c overexpression and HR less than 1 suggested a better prognosis. Statistical heterogeneity was assessed by visual inspection of forest plots, by performing the Chi-square test (assessing the P value), and by calculating the I 2 statistic [34, 35] . If the P value was less than 0.05 and/or I 2 exceeded 50%, indicating the presence of heterogeneity, a random-effects model (the DerSimonian-Laird method) was used. Otherwise, the fixedeffects model (the Mante-Haenszel method) was used. Subgroup analysis and meta-regression were further performed to explore the source of identified heterogeneity. Publication bias was estimated by visually assessing the asymmetry of an inverted funnel plot. Furthermore, Begg's and Egger's tests were performed to provide quantitative evidence of publication bias. If publication bias was observed, we adjusted for the effect by the use of the Duval and Tweedie trim-and-fill method [36] . For all analyses, STATA version 12.0 (Stata Corporation, College Station, TX, USA) was used with significance defined as a P-value of less than 0.05 except where otherwise specified.
Results

Study characteristics
Using the described searching strategy, 787 references were initially retrieved. After screening the titles, abstracts, publication types and full text of each publication, 23 articles including 25 studies that investigated the correlation between miR-200c expression and patient survival or disease recurrence in various malignant tumors were selected for the systemic review (Table 1) . A total of 2,534 patients from the United Kingdom, Germany, Spain, Poland, Japan, Sweden, Korea, Norway, Denmark, Italy, USA, China and Chinese Taiwan were diagnosed with a variety of cancers, including esophageal cancer [12, 19, 27] , gastric cancer [16, 25, 28] , colorectal cancer [8, 20, 29] , rectal cancer [30] , hepatocellular carcinoma [26] , pancreatic cancer [11] , lung cancer [13] , breast cancer [15] , diffuse large B-cell lymphoma (DLBCL) [18] , bladder cancer [10] , endometrial cancer [14, 17] , ovarian Shao et [9, 21, 23, 24] and prostate cancer [22] . In the primary reports, 11 studies showed a significant association between high miR-200c and poor prognosis [8, 9, 13, [15] [16] [17] [18] [19] [20] [21] [22] , 9 provided the opposite result [10, 11, 24-27, 29, 30] and 5 found no prognostic value of miR200c for tumor patients [12, 14, 20, 23, 28] . The expression of miR-200c was most often detected in tumor tissue samples, while five studies tested it in plasma or serum [15, 16, [20] . So 18 studies were identified in the 16 articles and were enrolled into the meta-analysis (Fig. 1 ) [10-17, 19, 20, 22, 24, 25, 27-29] . It has been previously reported that there was no association between serum miR-200c and miR-200c in primary tumor tissue [20] , thus we performed a meta-analysis based on both tissue and circulating miR-200c independently.
Quality assessment
Each of the 18 eligible studies included in our meta-analysis was assessed for quality according to the NOS. The quality of all studies included varied from 5 to 9, with a mean of 6.6. A higher value indicated better methodology. Therefore, all studies were included in the subsequent analysis.
Meta-analysis of tissue-based miR-200c overexpression
Of 18 studies, 12 studies reported data of tissue miR-200c expression and the prognosis, which included 1,405 cancer patients. All the HRs and corresponding 95% CIs from these articles are shown in Table 2 . Based on the 12 studies providing OS of patients [10-14, 17, 20, 24, 25, 28, 29 ], a random model was used to calculate the pooled HR and its 95% CI due to the high heterogeneity between these studies (P<0.001, I 2 =79.6%) ( Table 3 ). The results showed that high expression of tissue miR-200c was not associated with favorable OS in various carcinomas, with the pooled HR of 0.82 (95% CI 0.52-1.29, P=0.382) ( Table 3 ; Fig. 2A) . Because the two studies that reported DFS did not display obvious heterogeneity (P=0.884, I 2 =0%) (Table 3 ) [25, 29] , we calculated the pooled HR using a fixed model. The pooled HR revealed that tissue miR-200c overexpression significantly predicted better DFS Fig. 2B ). This conclusion was also found in other subgroups of colorectal cancer, ovarian cancer and ISH assay method used. However, the subgroup analysis of endometrial cancer indicated the opposite result. We did not find any significant association between miR-200c and prognosis in subgroups of patients with other stages, gastric cancer, qRT-PCR assay method used, multivariate or univariate analysis.
Meta-analysis of blood-based miR-200c overexpression
A total of six studies encompassing 723 tumor patients focused on blood miR-200c expression and the prognosis of patients [15, 16, 19, 20, 22, 27] . All the HRs and corresponding 95% CIs are shown in Table 4 . Five of six studies reported OS and displayed significant heterogeneity among them (P<0.001, I 2 = 82.6%) (Table 3) [15, 16, 20, 22, 27] . Therefore, a random model was applied to overall data integration, and we found that patients with high miR-200c levels in blood had a significantly poorer OS (HR=3.07, 95% CI 1.58-5.96; P=0.001) ( Table 3 ; Fig. 3A) . Because the three studies that reported PFS were not of obvious 
Heterogeneity Analysis
There was clear heterogeneity in 9 of the 16 analysis groups, as shown in Table 3 . The heterogeneity in the OS analysis group based on tissue miR-200c, which included 12 studies, was obvious (P<0.001, I 2 =79.6%), thus, a meta-regression was conducted to explore the factors that induced the obvious heterogeneity. As a result, the obvious heterogeneity was induced by tumor stage (P=0.044) rather than tumor type (P=0.170), analysis type (P=0.294), miR-200c assay method (P=0.344), patients origin (P=0.422), follow-up time (P=0.378), cutoff values (P=0.804) and publication year (P=0.916).
Publication Bias
The publication bias of all enrolled studies was evaluated using funnel plots, and Egger's and Begg's tests. The funnel plots of the OS analysis based on tissue and blood miR-200c were almost symmetric, as shown in Fig. 4 . In the 16 analysis groups, the P values of Egger's and Begg's tests were all greater than 0.05 (Table 3) . Hence, significant publication bias was not observed in our meta-analysis. 
Cellular Physiology and Biochemistry
Discussion
Metastasis is the spread of tumor cells from a primary tumor to a secondary site, and it remains the cause of 90% of deaths of cancer patients. Tumor metastasis is achieved by a series of intricate steps, including cell dissociation from the primary lesion, invasion into blood or lymphatic vessels, survival as microembolus in the circulatory system, extravasation and the formation of macroscopic foci in distant organs [37] [38] [39] . These steps are sequential and interrelated, and a failure or an insufficiency at any step can prevent the completion of metastasis. One of the key molecular steps in the process of distant metastasis is EMT, which permits invasion and emigration in various cancers [40, 41] . EMT is a complex process by which epithelial cells lose their epithelial cancer cell characteristics, but acquire a mesenchymal phenotype that is characterized by cell skeleton reorganization, motility, invasiveness and a heightened resistance to apoptosis [42] . Thus, EMT is thought to initiate early events of metastatic dissemination in carcinomas. The expression of cellular adhesion proteins such as E-cadherin and γ-catenin is significantly downregulated during the EMT process, while the expression of mesenchymal markers such as vimentin and N-cadherin is upregulated. [6] . The functional loss of E-cadherin is a well-known hallmark of EMT and is accomplished generally through altered expression of the CDH1 transcriptional repressors, such as ZEB1/2, SNAI1/2, Twist1/2 and others [43] [44] [45] [46] . In physiological conditions, the shift from EMT to MET is a necessary step in tissue construction. Similar to metastasis, tumor cells also undergo MET to facilitate the establishment of macroscopic metastases [42, 47, 48] .
The miR-200 family members play an important role in regulating metastasis. Particularly, miR-200c plays critical roles in inhibiting EMT and promoting MET by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. It is well documented that highly expressed miR-200c in epithelial cancer cells represses the expression of ZEBs, whereas impaired expression of miR-200c in mesenchymal cancer cells leads to upregulation of ZEBs and induces downregulation of E-cadherin [2] [3] [4] 49] . Some studies have revealed that the expression of miR-200c is impaired in various human tumors, such as bladder cancer, gastric cancer, pancreatic cancer, esophageal cancer, colorectal cancer and ovarian cancer, thereby inducing EMT and disease progression [10, 11, 24, 25, 27, 29, 50] . In addition, miR200c plays a crucial role in regulating stem cell self-renewal and differentiation. By targeting B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a known regulator for stem cell self-renewal, miR-200c strongly suppresses the ability of normal mammary stem cells to form mammary ducts and decreases tumor formation driven by human breast cancer stem cells (CSCs) in vivo [51] . These data collectively indicate that the miR-200c may act as a tumor suppressor. However, upregulation of miR-200c has been found in multiple tumors including NSCLC, breast cancer, ovarian cancer and endometrial cancer [9, 13, 15, 17, 52] , indicating that miR-200c may also exhibit oncogenic potential, likely due to over expression of miR-200c increasing metastatic risk by the induction of MET. Thus, it is controversial miR200c expression can be used as a prognostic biomarker in different cancers.
Recently, a meta-analysis reported by Wang et al. [53] assessed the correlation between miR-200c and prognosis of patients with malignant tumors, and the results demonstrated that low expression of miR-200c in tumor tissue and high expression of miR-200c in serum were associated with worse survival in solid tumors. However, its search of relevant literature was limited to PubMed and just contained 6 articles. Obviously, it's not comprehensive enough to collect all relevant evidence available from the literature, and the strength of their conclusions was doubtful. In this study, we search the literature through PubMed, Embase and the Cochrane Library, and 19 articles are enrolled. The conclusion of this meta-analysis is different from Wang et al.'s, and we believe it is more powerfully evidence-based and credible. In this systemic review and meta-analysis, all the studies that reported the prognostic value of miR-200c in patients with malignant tumors did not come to an accordant conclusion. In this systematic review, we found that low expression of tissue miR-200c was a negative prognostic factor in groups consisted mainly of early cancer patients. With the increased [7, 20] . This result also supports the theory we propose here: the expression of miR-200c in primary tissue and blood can be a valuable prognostic biomarker for patients with early stage and advanced tumors, respectively. However, some details need to be further refined. First, this study only included only 18 eligible studies, which resulted in relatively insufficiency data in the subgroup analyses. Second, due to the lack of a unified cut-off value in miR-200c expression, different cut-off values were used in those studies. The inaccurate cut-off values may affect the availability of miR-200c as a predictive biomarker in cancer prognosis. Third, several HRs were calculated based on the data extracted from the survival curves, which inevitably leads to small statistical errors. Fourth, there was significant heterogeneity displayed in our meta-analysis and most likely due to variation in patient origin, publication year, tumor type, tumor stage, miR-200c assay method, analysis type, follow-up time, cut-off values among others. Finally, although there was no significant publication bias found in this meta-analysis, the sample size was still not large enough to determine the existence of publication bias.
Conclusion
In conclusion, we found that low expression of miR-200c in primary tissue was significantly associated with poor survival in cancer patients at an early stage of disease, whereas high level of miR-200c in blood could predict poor prognosis in patients with advanced tumors. Considering the limitations of present analysis, the conclusions should be regarded cautiously. Further prospective multi-center studies with larger sample size are needed to test the association between miR-200c and cancer prognosis, as well as to explore effective therapies. Besides, the results of this meta-analysis also suggest the opposite effects
